CLINICAL TRIALS PROFILE FOR FIRVANQ KIT

All Clinical Trials for FIRVANQ KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06148025 ↗	Antibiotics and Vaccine Immune Responses Study	Recruiting	Centenary Institute of Cancer Medicine and Cell Biology	Phase 4	2023-11-23	The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
NCT06148025 ↗	Antibiotics and Vaccine Immune Responses Study	Recruiting	Flinders University	Phase 4	2023-11-23	The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
NCT06148025 ↗	Antibiotics and Vaccine Immune Responses Study	Recruiting	Royal Adelaide Hospital	Phase 4	2023-11-23	The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
NCT06148025 ↗	Antibiotics and Vaccine Immune Responses Study	Recruiting	Telethon Kids Institute	Phase 4	2023-11-23	The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
NCT06148025 ↗	Antibiotics and Vaccine Immune Responses Study	Recruiting	University of Sydney	Phase 4	2023-11-23	The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Clinical Trial Conditions for FIRVANQ KIT

Condition Name

Condition Name for FIRVANQ KIT
Intervention	Trials
Vaccine Response Impaired	1

Condition MeSH

Condition MeSH for FIRVANQ KIT
Intervention	Trials

Clinical Trial Locations for FIRVANQ KIT

Trials by Country

Trials by Country for FIRVANQ KIT
Location	Trials
Australia	1

Clinical Trial Progress for FIRVANQ KIT

Clinical Trial Phase

Clinical Trial Phase for FIRVANQ KIT
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for FIRVANQ KIT
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for FIRVANQ KIT

Sponsor Name

Sponsor Name for FIRVANQ KIT
Sponsor	Trials
Centenary Institute of Cancer Medicine and Cell Biology	1
Flinders University	1
Royal Adelaide Hospital	1

Sponsor Type

Sponsor Type for FIRVANQ KIT
Sponsor	Trials
Other	6

FIRVANQ KIT clinical trials update, market analysis, and revenue projection (FDA, IP, and competitive landscape)

Last updated: July 30, 2026

No complete, decision-grade clinical trials, market, and projection dataset for FIRVANQ KIT is available in the provided context to produce an accurate, citation-backed update and forecast.

What is FIRVANQ KIT and what active ingredient does it contain?

Answer: Cannot be determined from the provided context.

What dosage forms and administration method does FIRVANQ KIT include?

Cannot be determined from the provided context.

Is FIRVANQ KIT a prescription drug, OTC product, or device-drug combination?

Cannot be determined from the provided context.

What clinical trials have been completed for FIRVANQ KIT, and what endpoints were reported?

Answer: Cannot be determined from the provided context.

What phase trials exist for FIRVANQ KIT (Phase 1, 2, 3)?

Cannot be determined from the provided context.

What are the latest recruitment status updates (active, recruiting, completed, terminated)?

Cannot be determined from the provided context.

What safety and efficacy results are reported for FIRVANQ KIT?

Cannot be determined from the provided context.

When did FIRVANQ KIT enter clinical development, and what is the regulatory timeline?

Answer: Cannot be determined from the provided context.

Has FIRVANQ KIT received FDA approval, and for what indication?

Cannot be determined from the provided context.

What FDA review pathway applies (505(b)(1), 505(b)(2), 510(k), De Novo, BLA/NS)?

Cannot be determined from the provided context.

What are the key FDA milestones (CRL, PDUFA date, labeling updates)?

Cannot be determined from the provided context.

What is the Orange Book status of FIRVANQ KIT, and what patents protect it?

Answer: Cannot be determined from the provided context.

Which patents are listed (drug product, method of use, formulation, polymorph)?

Cannot be determined from the provided context.

When do patents expire, and what exclusivity periods apply (NCE, 5-year, 3-year, pediatric)?

Cannot be determined from the provided context.

Are there Paragraph IV filings challenging FIRVANQ KIT?

Cannot be determined from the provided context.

What is the market size for FIRVANQ KIT and where does it fit in the therapeutic category?

Answer: Cannot be determined from the provided context.

What patient population drives demand for FIRVANQ KIT?

Cannot be determined from the provided context.

What payer dynamics and reimbursement benchmarks apply (US commercial vs Medicare vs Medicaid)?

Cannot be determined from the provided context.

What is the current branded uptake pattern (scripts, NBRx, new starts)?

Cannot be determined from the provided context.

How does FIRVANQ KIT compare with existing standard of care and competitors?

Answer: Cannot be determined from the provided context.

What are the major alternative products (drug class, mechanism, route)?

Cannot be determined from the provided context.

What differentiators matter for formulary positioning (speed of onset, dosing frequency, administration convenience)?

Cannot be determined from the provided context.

Where does efficacy and safety land versus comparators?

Cannot be determined from the provided context.

What commercial forecasts can be projected for FIRVANQ KIT (base, upside, downside)?

Answer: Cannot be determined from the provided context.

Revenue projection model inputs required for FIRVANQ KIT

Cannot be determined from the provided context.

Forecast horizon (2025-2035) and scenario assumptions

Cannot be determined from the provided context.

Geographic split assumptions (US vs EU5 vs UK vs other markets)

Cannot be determined from the provided context.

What generic or biosimilar entry risks exist for FIRVANQ KIT?

Answer: Cannot be determined from the provided context.

What is the likelihood of ANDA entry under current IP and exclusivity?

Cannot be determined from the provided context.

What is the risk timeline to first generic competition?

Cannot be determined from the provided context.

What manufacturing/IP barriers could block generic launches?

Cannot be determined from the provided context.

What patent litigation and settlements affect FIRVANQ KIT?

Answer: Cannot be determined from the provided context.

Are there active cases in Delaware, DC, or other jurisdictions?

Cannot be determined from the provided context.

What settlement terms (design-arounds, licensing, launch dates) are on record?

Cannot be determined from the provided context.

Key Takeaways

• FIRVANQ KIT clinical trials, regulatory status, IP protection, market sizing, competitive set, and revenue forecasts cannot be produced accurately from the provided context.

FAQs

1. Is FIRVANQ KIT an FDA-approved product or still in trials?
2. What trials support FIRVANQ KIT’s claimed indication?
3. What patents and exclusivity periods delay generic entry for FIRVANQ KIT?
4. Which competitors are most likely to pressure FIRVANQ KIT pricing and share?
5. What is the highest-impact milestone for FIRVANQ KIT over the next 12 to 24 months?

References (APA)

1. (No cited sources available from the provided context.)